Who is sponsoring NCT03167775?

NCT03167775 is sponsored by BeiJing Yijiayi Medicine Techonoloy Co., Ltd..

What drugs are being tested in NCT03167775?

Interventions in NCT03167775: Elemene Injection/Elemene Oral Emulusion.

What condition does NCT03167775 study?

NCT03167775 studies Advanced Primary Liver Cancer.

Is NCT03167775 still recruiting?

NCT03167775 is currently status unknown. Last updated 30 May 2017.

Last reviewed 2017-05-30 · How we verify

NCT03167775

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer

Status unknown NA Last updated 30 May 2017

What this trial tests

NA trial testing Elemene Injection/Elemene Oral Emulusion in Advanced Primary Liver Cancer in 30 participants. Status unknown.

Timeline

28 November 2016

Primary endpoint
27 May 2019

27 November 2019

Quick facts

Lead sponsor	BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	28 November 2016
Primary completion	27 May 2019
Estimated completion	27 November 2019
Sites	1 location across China

Drugs / interventions tested

Elemene Injection/Elemene Oral Emulusion — full drug profile →

Conditions studied

Advanced Primary Liver Cancer — all drugs for Advanced Primary Liver Cancer →

Sponsor

BeiJing Yijiayi Medicine Techonoloy Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Primary Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling.
Koeberle SC, Kipp AP, Stuppner H, Koeberle A. · · 2023 · cited 74× · PMID 36658724 · DOI 10.1002/med.21933
Development of modern Chinese medicine guided by molecular compatibility theory.
Luo L, Zhou J, Liu X, Chen Y, et al · · 2025 · cited 12× · PMID 39111627 · DOI 10.1016/j.jare.2024.08.005

Verify or expand the search:

Other BeiJing Yijiayi Medicine Techonoloy Co., Ltd. trials

Trials by the same sponsor.

NCT03413358 — Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid · NA · unknown
NCT03166553 — Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03167775 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Last refreshed: 30 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03167775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing